Polyethylene Glycol Electrolyte Solution

Introduction Overview

Generic Name

polyethylene glycol electrolyte solution

Brand Name

GoLYTELY

Dosage Form

Oral powder to be mixed with water to form a laxative solution

Drug Class

Laxatives

Pharmacokinetics

Absorption:
GoLYTELY contains polyethylene glycol 3350 (PEG-3350) combined with electrolytes. PEG-3350 is a large, non-absorbable, hydrophilic polymer that remains largely within the gastrointestinal tract upon oral administration. It is minimally absorbed systemically, which underlies its safety profile as a bowel cleansing agent. The electrolytes present, such as sodium sulfate, sodium chloride, potassium chloride, and sodium bicarbonate, are similarly negligibly absorbed as they primarily act within the gut lumen to maintain electrolyte balance during the induced bowel movements. The lack of significant absorption minimizes systemic exposure and associated systemic side effects.

Distribution:
Given the minimal intestinal absorption, distribution of polyethylene glycol and the accompanying electrolytes into systemic circulation is negligible. As a result, the drug exerts its effect locally in the gastrointestinal tract without systemic distribution or accumulation. Electrolytes replaced in the solution help maintain plasma electrolyte homeostasis during bowel cleansing, but the solution does not significantly alter systemic distribution as it avoids absorption.

Metabolism:
Polyethylene glycol 3350 is not metabolized by the body. It remains unchanged as it passes through the intestine and is excreted in the feces. The stable chemical structure of PEG-3350 prevents enzymatic breakdown. The electrolytes included are natural ions that are either minimally absorbed or passed unchanged through the digestive tract. Therefore, hepatic metabolism does not play a role in the clearance of GoLYTELY components.

Elimination:
The elimination of polyethylene glycol is by fecal excretion without transformation or absorption. The solution creates an osmotic gradient that retains water in the colon, softening stool and stimulating bowel movements, thereby rapidly clearing intestinal contents. Electrolytes maintain fluid and electrolyte balance while being lost via stool. Renal elimination is not a primary route since systemic absorption is minimal. The rapid transit and prompt bowel evacuation typically occur within 1–2 hours after initiation of ingestion, with complete evacuation within a few hours depending on dosing.

Dosage Forms

Available Dosage Forms:
GoLYTELY is supplied as an oral powder that must be diluted with water to prepare a laxative solution. The powder is packaged in large-volume powder containers to make approximately 4 liters of reconstituted solution intended for bowel cleansing prior to colonoscopy or other intestinal procedures. It is designed for oral intake following specific preparation protocols.

Dosages for Adults and Adolescents:
The standard dosing regimen typically involves consuming the entire 4-liter solution over a prescribed period, often divided into split doses (e.g., half on the evening before and half on the morning of the procedure). Patients are advised to drink the solution in liters at a steady pace, often maintaining consumption over 2 to 4 hours. The dosing is strictly as per the prescribing physician's instructions and the specific formulation's guidelines to ensure effective bowel cleansing.

Specific Patient Populations:
Patients with renal impairment, heart disease, electrolyte imbalances, or those at risk of fluid overload require close monitoring when using GoLYTELY due to the potential risk of fluid and electrolyte disturbances. Pediatric dosing is less common and typically specialized. Elderly patients may require adjusted timing or monitoring due to changes in renal function. Patients with known allergies to PEG or electrolyte components should avoid use.

Preparation and Administration:
The powder must be reconstituted by adding to water only, without any flavorings, juices, sugars, or other additives which may interfere with efficacy. The solution should be shaken well before measuring doses, and it is recommended to store mixed solutions refrigerated and consume within 24 to 48 hours. Clear liquids are encouraged in parallel during administration, while avoiding colored or pulp-containing beverages.

Mechanism Of Action

GoLYTELY acts primarily as an osmotic laxative through the action of polyethylene glycol 3350 combined with electrolytes. PEG-3350 is a large, hydrophilic polymer that binds and retains water molecules in the intestinal lumen by osmosis, dramatically increasing the stool water content and volume. This increase in luminal water softens stools and stimulates bowel motility, promoting rapid evacuation without stimulating colonic secretions or absorption alterations.

The inclusion of electrolytes such as sodium sulfate, sodium chloride, potassium chloride, and sodium bicarbonate prevents significant shifts in systemic electrolytes by replacing ions lost during the purgative process. These electrolytes maintain isotonicity, minimizing net absorption or secretion of water and electrolytes in the colon, thereby avoiding disturbances like dehydration or electrolyte imbalances that are common with other laxatives.

On a cellular level, PEG-3350 does not undergo metabolism or interact with enterocyte receptors but works physically by retaining water in the gut lumen, which distends the colon and activates stretch receptors. This distension then triggers peristaltic reflexes, resulting in bowel movements. Unlike stimulant laxatives, GoLYTELY does not induce direct intestinal mucosal irritation or excessive secretion of fluids.

Clinically, this mechanism ensures effective bowel cleansing necessary for diagnostic procedures such as colonoscopy or barium enema without causing significant discomfort or systemic toxicity. Studies demonstrate that it produces predictable, thorough colonic emptying with a favorable safety profile compared to earlier bowel prep agents, making it a preferred agent for colonoscopy preparation.

Pharmacological Actions

Acts as an osmotic laxative by retaining water in the intestinal lumen via polyethylene glycol 3350
Contains electrolytes to replace those lost during laxative-induced bowel movements, maintaining electrolyte balance
Induces increased stool water content and volume leading to mechanical stimulation of bowel motility
Does not undergo systemic absorption, minimizing systemic exposure and toxicity
Does not stimulate intestinal secretions or cause mucosal irritation directly
Facilitates rapid, effective bowel cleansing necessary for diagnostic and therapeutic intestinal procedures
Preserves isotonicity in the gastrointestinal tract to prevent fluid shifts and dehydration
Generally well tolerated with minimal systemic side effects due to local mechanism
Avoids altering colonic motor function beyond necessary peristaltic activation
Compatible with other medications given separate timing due to minimal absorption interference
Effective in clearing bowel contents within 1 to 4 hours post ingestion
Minimal interaction with metabolic enzymes, as it is not metabolized
Electrolyte components help prevent potential imbalances and maintain mucosal integrity during cleansing
Does not cause dependency or habituation seen with stimulant laxatives
Has a well-documented safety profile in both outpatient and inpatient bowel preparation settings

Therapeutic Or Clinical Uses

Bowel cleansing prior to colonoscopy to ensure clear visualization of the mucosa
Preparation for barium x-ray studies of the intestine
Preoperative bowel preparation before colorectal surgery or other surgical procedures requiring an empty colon
Adjunct treatment in diagnostic and therapeutic gastrointestinal procedures needing complete evacuation of feces
Occasionally used for acute management of severe constipation under medical supervision
Electrolyte replenishment during induced bowel evacuation prevents hypovolemia and electrolyte imbalances
Useful in patients requiring rapid colonic cleansing with minimal systemic side effects
Preferred agent for bowel prep in patients with cardiac or renal concerns due to balanced electrolyte formulation
Can be utilized in patients with risk factors for dehydration, if appropriate monitoring is provided
Often combined with dietary modifications and fluid intake guidance for effective bowel prep
Supportive role in GI decontamination procedures in cases of poisoning requiring evacuation
Employed in clinical research studies as a standardized colon cleansing agent
Used in both inpatient and outpatient settings for bowel preparation due to ease of use and efficacy
Alternative to stimulant laxatives for patients intolerant or contraindicated to such agents
Necessary bowel preparation for accurate colorectal cancer screening and surveillance procedures

Side Or Adverse Effects

Vomiting, nausea, and occasional stomach pain or cramping
Indigestion and bloating sensations due to bowel distension
Rectal pain or irritation from frequent bowel movements
Mild dehydration causing thirst or dry mouth if fluid intake is insufficient
Dizziness or chills potentially related to fluid or electrolyte imbalance
Allergic reactions including rare cases of hives, swelling, or breathing difficulty
Electrolyte disturbances presenting as muscle pain, weakness, cramps, irregular heartbeat, or tingling sensations
Severe adverse effects like seizure or fainting associated with significant electrolyte imbalance
Possible headache or trouble sleeping secondary to dehydration or electrolyte changes
Rare risk of serious bowel injury such as perforation if used in contraindicated conditions
Gagging or choking sensation when ingesting large volumes of solution rapidly
Signs of bowel obstruction or severe constipation flare with improper use
Fever or severe diarrhea indicating potential GI infection or colitis
Rectal bleeding or bright red blood in stool requiring medical attention
May cause electrolyte abnormalities especially in vulnerable populations without medical monitoring

Precautions

Do not use if there is a known allergy to polyethylene glycol or electrolyte components
Avoid use if there is a perforated bowel, bowel obstruction, severe constipation, colitis, or toxic megacolon
Patients with electrolyte imbalances, kidney disease, or cardiac conditions require medical supervision
Not recommended for individuals with eating disorders without physician approval
Use caution in patients with difficulty swallowing, aspiration risk, or severe gastrointestinal diseases
Requires strict adherence to preparation instructions to prevent inadequate bowel cleansing and complications
Avoid adding flavorings, sugars, or other liquids to the solution that may reduce efficacy
Do not take other laxatives concurrently unless prescribed by healthcare provider
Maintain adequate hydration before, during, and after administration to prevent dehydration
Avoid solid food intake within one hour prior to drinking GoLYTELY solution
Store unmixed powder away from moisture and heat, mixed solution refrigerated and consumed promptly
Report any side effects suggestive of electrolyte imbalance, dehydration, or allergic reaction immediately
Pregnant and breastfeeding women should consult their physician before use
Monitor closely in elderly due to potential changes in fluid and electrolyte balance
Do not consume colored or pulp-containing beverages or foods during preparation to avoid interference with procedure

Warnings

Do not use if you have a perforated bowel or suspected bowel obstruction
Contraindicated in severe constipation, colitis, or toxic megacolon
Use with caution in patients with heart disease due to risk of fluid and electrolyte disturbances
Potential for serious or life-threatening electrolyte imbalances if guidelines are not followed
Avoid use without medical supervision in patients with history of seizure or electrolyte disturbances
Risk of aspiration in patients with swallowing difficulties or neurological impairment
Stop use and seek medical help if no bowel movement occurs within 2 hours of starting
Discontinue if severe vomiting, dizziness, or minimal urination occurs during preparation
Risk of dehydration and related complications if fluid intake is insufficient
Not to be mixed with other substances that may impair bowel cleansing or cause adverse reactions
Avoid use in patients with phenylketonuria if solution contains phenylalanine without physician guidance
Must be used exactly as directed to prevent interference with diagnostic procedure
Do not eat or drink anything within 2 hours before the planned colonoscopy or intestinal procedure
Improper preparation can lead to inadequate bowel visualization and failed procedures
Potential for hypersensitivity reactions including anaphylaxis that require emergency attention

Contraindication

Known hypersensitivity or allergy to polyethylene glycol or any of the electrolyte components
Perforated bowel due to risk of exacerbating perforation and peritonitis
Bowel obstruction or severe constipation which may worsen obstruction and lead to bowel ischemia
Colitis or toxic megacolon where bowel cleansing could precipitate dangerous complications
Patients with underlying gastrointestinal inflammatory diseases without clearance from physician
History of hypersensitivity reactions to similar laxative preparations
Conditions predisposing to fluid overload without appropriate monitoring
Children under specific age or weight limits unless prescribed with specialized guidance
Presence of severe electrolyte or fluid imbalance prior to administration
Use not recommended in patients with impaired swallowing or aspiration risk without close supervision
Patients with untreated phenylketonuria if the preparation contains phenylalanine
Concurrent use with other bowel-cleansing agents unless directed by a physician
Pregnancy and lactation only if benefit outweighs risk and under medical advice
Known or suspected gastrointestinal perforation or ileus
Patients with glucose-6-phosphate dehydrogenase deficiency may require assessment before use

Drug Interactions

Concurrent use with diuretics may increase risk of electrolyte imbalances such as hypokalemia
NSAIDs may compound the risk of renal impairment or electrolyte disturbances during bowel prep
Medications for heart or blood pressure conditions require monitoring due to fluid shifts
Seizure medications efficacy may be altered if electrolyte imbalances occur
Antidepressants or psychiatric medications may have altered absorption due to rapid GI transit
Other oral medications may have reduced absorption efficacy if taken within 1 hour of GoLYTELY
Drug interactions with potassium or sodium altering drugs may increase risk of arrhythmias
Heart medications such as digoxin may require monitoring for toxicity due to electrolyte changes
Concurrent use with lithium may require monitoring as lithium elimination can be affected by hydration status
Anticoagulants and antiplatelet drugs may complicate bleeding risks if mucosal irritation occurs
Co-administration with other laxatives or purgatives can increase risk of dehydration and side effects
Drugs affecting kidney function may require dose adjustment when used with GoLYTELY
Ingestion of sorbitol or sugar-containing products with GoLYTELY may alter osmotic effect and cleansing efficacy
Herbal supplements with laxative or diuretic effects may potentiate GoLYTELY effects
Any concurrent medications should be reviewed carefully and timed appropriately to avoid absorption interference

Preparations Of The Drug

GoLYTELY oral powder which is to be diluted with water to make approximately 4 liters of solution
Packaged with instructions for mixing only with water, excluding juices, sweeteners, and other liquids
Flavored and unflavored formulations available depending on manufacturer and brand
Solution contains polyethylene glycol 3350 combined with electrolytes: sodium sulfate, sodium chloride, potassium chloride, and sodium bicarbonate
Commercially available as single-use powder containers designed for one colon cleansing procedure
Some brand variants include flavor packs to improve palatability (e.g., lemon, orange)
Ready-to-use solutions are generally not marketed; mixing must occur just before administration
Storage instructions for unmixed powder indicate room temperature away from moisture and heat
Reconstituted solutions require refrigeration and should be consumed within 24 to 48 hours
Instructional leaflets accompany products detailing dosing regimens, timing, and dietary guidelines
Different branded PEG-electrolyte solutions exist with similar formulations (GaviLyte-C, NuLYTELY, etc.)
Some formulations are approved for pediatric use with adjusted dosing under specialist guidance
Packaging often includes dosing devices or measuring cups to ensure accurate preparation
Patient education materials emphasize the importance of adherence to preparation protocols for efficacy
Manufacturer recommended to not alter preparation steps to maintain osmotic laxative properties and safety